Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Neogene Therapeutics Inc.

Headquarters: New York, NY, United States of America
Website: N/A
Year Founded: 2018
Status: Acquired

BioCentury | Nov 23, 2024
Finance

Latest Jeito bet positions European VC for fourth exit

Mega-round for Alentis spotlights French firm’s investment style 
BioCentury | May 22, 2024
Deals

Biogen’s ‘pick and choose’ strategy in immunology leads to $1B HI-Bio takeout

Continuing diversity push under Viehbacher, Biogen obtains two programs spun out from MorphoSys, backed by Arch, Monograph, Jeito and others
BioCentury | Nov 10, 2023
Management Tracks

New CFO, CMO at TreeFrog

Plus: Metagenomi names Borges CSO and Wapnick CFO, and updates from Teva, Century, Assembly and more
BioCentury | Oct 31, 2023
Management Tracks

CSO, CFO changes at Third Harmonic

Plus: MediLink hires Steve Chin as CMO, and updates from ImmPACT, 
BioCentury | May 2, 2023
Management Tracks

Azam named CEO at Inspirna

Plus: Day One promotes Blackman to head of R&D, and updates from Esperovax, Ring, Alladapt, Innoviva and more
BioCentury | Feb 22, 2023
Management Tracks

Gandhi named CMO at NextPoint

Plus: Mathias to become CEO at Oxford, and updates from Novartis and Shoreline
BioCentury | Dec 17, 2022
Product Development

Neoantigens Part III: Picking up the pace

The field ends a busy 4Q22 with Moderna’s highly anticipated, heavily scrutinized data
BioCentury | Nov 29, 2022
Deals

Galbraith’s commitment to cell therapy leads AZ to buyout of Neogene

Shareholders to receive $200M up front, up to $120M more; realize exit just over two years after series A
BioCentury | Nov 1, 2022
Product Development

Neoantigens Part II: cell therapies

An overview of the growing field, company players and emerging data
BioCentury | Jan 12, 2022
Deals

Jan. 11 Quick Takes: Roche cash infusion brings Freenome’s overall haul to $1.1B

Plus: NCI licenses for Neogene, Sana and updates from Allogene-Antion, Illumina bluebird, ONK, Gameto
Items per page:
1 - 10 of 23